Climb Bio, Inc. Common Stock (CLYM) Stock
NASDAQ · CLYM
11.69
Fundamentals
Market cap
$669.71M
Price / Earnings ratio
-11.9x
Price / Sales ratio
N/A
Price / Book ratio
2.9x
Return on assets
-30.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Investors Business Daily
Biotech Stocks Dive As Top 2% Names Take Hardest Hit
NeutralCLYMSeptember 23, 2026
Investors Business DailyNeutral
Biotech Stocks Dive As Top 2% Names Take Hardest Hit
CLYM

MarketBeat
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
NeutralCLYMSeptember 3, 2026
MarketBeatNeutral
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
CLYM

Investors Business Daily
Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
NeutralCLYMSeptember 3, 2026
Investors Business DailyNeutral
Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
CLYM

MarketBeat
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
NeutralCLYMMay 21, 2026
MarketBeatNeutral
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
CLYM
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy7
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
201M133M66M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-59.9M
Net incomeEarnings
No data available
% positive news of 4 articles
published over the past 14 days
Latest news

Investors Business Daily
Biotech Stocks Dive As Top 2% Names Take Hardest Hit
NeutralCLYMSeptember 23, 2026
Investors Business DailyNeutral
Biotech Stocks Dive As Top 2% Names Take Hardest Hit
CLYM

MarketBeat
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
NeutralCLYMSeptember 3, 2026
MarketBeatNeutral
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
CLYM

Investors Business Daily
Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
NeutralCLYMSeptember 3, 2026
Investors Business DailyNeutral
Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
CLYM

MarketBeat
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
NeutralCLYMMay 21, 2026
MarketBeatNeutral
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
CLYM
About Climb Bio, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees28
CEODr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
IPO DateAug 5, 2021
HeadquartersWellesley Hills, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | CEO, President & Director | 1976 |
| Dr. Susan Altschuller M.B.A., Ph.D. | CFO & Principal Accounting Officer | 1982 |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer | 1979 |
| Mr. Adam Villa | Senior Vice President of Technical Operations | — |
| Ms. Chandra Adams J.D. | Senior VP, General Counsel & Secretary | — |
| Ms. Ashley Jones | Senior Vice President of People & Workforce Strategy | — |
| Dr. Edgar D. Charles M.D., M.Sc. | Chief Medical Officer | — |
Fundamentals
Valuation
Market cap$669.71M
Price-to-sales ratioN/A
Price-to-book value2.85
Price-earnings ratio-11.90
Return on Equity-32.00%
Return on SalesN/A
Return on Assets-30.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.82
Income Statement
Average volume1,816,167
EBITDA$-52.44M
1 year high (52w)$18.33
1 year low (52w)$1.54
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
7 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$26.71
Est return
132.50%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -24.9 | -15.4 | -44.8 | |||||||||
| 2025 | -8.2 | -27.1 | -9.6 | +11.7 | -6.3 | +5.1 | +17.6 | +53.8 | -9.9 | +4.1 | -5.5 | +123.5 |
| 2026 | +19.2 | +51.2 | -3.1 | +27.8 | +23.0 | +10.5 | -10.5 | +16.3 | -21.3 |



